A Phase I/II randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
The COVID-19 pandemic highlighted an urgent need for efficient, durable, and widely accessible vaccines. This prompted several important innovations in vaccine technology, and researchers continue to ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that it has received a US$5 million [AU$7.5 ...
ANDERNACH, Germany, Dec. 19, 2023 /PRNewswire/ -- LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The purpose ...
Researchers have used 3D-printing technology to improve the viral titer of microneedle array patches, resulting in effective immunogenicity and protection against infection in mice. (Nanowerk News) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results